Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11299302 | 1.00 | KMT2A (0.49) | KMT2APOLBALDH1A1HPGDPGR | |
| SCHEMBL14999393 | 0.80 | POLB (0.51) | KMT2APOLBALDH1A1HPGDPGR | |
| SCHEMBL8636414 | 0.80 | POLB (0.51) | KMT2APOLBALDH1A1HPGDPGR | |
| SCHEMBL10932521 | 0.78 | KMT2A (0.50) | KMT2APOLBALDH1A1HPGDPGR | |
| SCHEMBL673023 | 0.78 | POLB (0.50) | KMT2APOLBALDH1A1HPGDPGR | |
| SCHEMBL10932532 | 0.78 | KMT2A (0.50) | KMT2APOLBALDH1A1HPGDPGR | |
| SCHEMBL20334041 | 0.78 | KMT2A (0.41) | KMT2APOLBALDH1A1HPGDPGR | |
| SCHEMBL14975956 | 0.77 | KMT2A (0.49) | KMT2APOLBALDH1A1HPGDMAPT | |
| SCHEMBL14975958 | 0.77 | KMT2A (0.49) | KMT2APOLBALDH1A1HPGDMAPT | |
| SCHEMBL3082044 | 0.77 | KMT2A (0.40) | KMT2APOLBALDH1A1HPGDPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56022704-A | — | — | None | — | — | JP | disclosed |
| US-10662211-B2 | Catalysts and methods for polymer synthesis | Saurdi Aramco Technologies Company (SA) | 2020-05-26 | — | — | US | disclosed |
| US-20180179242-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. | 2018-06-28 | — | — | US | disclosed |
| US-9951096-B2 | Catalysts and methods for polymer synthesis | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2018-04-24 | — | — | US | disclosed |
| US-20170107241-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NOVOMER, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| JP-S5622704-A | AGRICULTURAL AND HORTICULTURAL GERMICIDE | UBE IND LTD | 1981-03-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107241-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NCLN, POLN, NCL | KMT2A 3824/4885POLB 193/4885ALDH1A1 3519/4885 |
| US-10662211-B2 | Catalysts and methods for polymer synthesis | PPOX, COASY, SOD1 | KMT2A 1825/4885POLB 121/4885ALDH1A1 2255/4885 |
| US-20180179242-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | KMT2A 1825/4885POLB 121/4885ALDH1A1 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.